AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03839407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MUSE Meditation Device
Description: The MUSE Meditation Device guides users in mindful meditation using real-time feedback on brain wave activity.
Study NCT01877863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: 12 weeks of intradialytic biking at Borg intensity 3 - 4 for 15 to 60 minutes on each dialysis run
Study NCT01672788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: empagliflozin tablets and metformin tablet
Study NCT01672788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin + Metformin
Description: fixed dose combination tablet (low)
Study NCT01672788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: empagliflozin tablets and metformin tablet
Study NCT01672788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: empagliflozin tablet and metformin tablet
Study NCT01672788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: empagliflozin tablet and metformin tablet
Study NCT01509326 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chiropractic treatment
Description: 12 sessions over 4 weeks
Study NCT01509326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dr. Zaxx pillow
Description: Daily use of an acupressure pillow
Study NCT04271007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone Furoate
Description: mometasone furoate
Study NCT01940354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCath IV Catheter System
Description: Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
Study NCT01940354 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional IV Catheter System
Description: Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples
Study NCT01538953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: handwashing
Description: participants received weekly in-home handwashing promotion and soap as needed
Study NCT01538953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flocculent-disinfectant for water treatment
Description: participants received a supply of flocculent-disinfectant product for water treatment and instruction in how to use it
Study NCT01538953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water treatment with sodium hypochlorite
Description: participants received a supply of dilute sodium hypochlorite and instruction to treat drinking water with it
Study NCT02367235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional vaginal positioning device
Description: A vaginally placed endo-anal sizer will be used to position the vagina during surgery.
Study NCT02367235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colpassist vaginal positioning device
Description: A vaginally placed Colpassist will be used to position the vagina during surgery.
Study NCT04820777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perturbation training
Description: external or internal postural perturbations. External perturbations occur by forces outside the patient' control (e.g., a push or pull from the physiotherapist). Internal perturbations caused when the patient is unable to control the centre of mass and the base of support relationship during voluntary movement; 'agility' tasks, such as kicking a soccer ball,
Study NCT04820777 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional' balance training
Description: Starting from a situated position, expand your left leg until it's corresponding to the floor. Try not to bolt your knee. At that point, gradually bring your foot down to the floor. Rehash with your correct leg, exchanging to and fro between legs for a s
Study NCT04578912 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Description: CBIT is a manualized treatment program focused on tic management skills
Study NCT04578912 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Description: CBIT is a manualized treatment program focused on tic management skills
Study NCT04578912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: During repetitive transcranial magnetic stimulation (rTMS), a electromagnetic coil is placed against the scalp while an electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the target brain region
Study NCT04578912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Theta Burst Stimulation (cTBS)
Description: During continuous theta burst stimulation (cTBS), a electromagnetic coil is placed against the while an electromagnet painlessly delivers magnetic bursts that stimulate nerve cells in the target brain region
Study NCT01873495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine
Description: Omacetaxine 1.25 mg/m² sub-cutaneously twice daily for 5 consecutive days every 28 (± 8) days for 3 cycles.~Patients in continuous remission after 3 cycles of consolidation will receive maintenance omacetaxine 1.25 mg/m² twice daily for 3 days, every 28 days for up to 6 cycles
Study NCT03873493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets taken orally once a day (QD). Initially, venetoclax was administered utilizing a 5-step dose ramp-up over 5 days. Subjects were hospitalized and closely monitored for 7 days. The venetoclax ramp-up was administered in a daily manner: 20 mg on Week 1 Day 1, 50 mg on Week 1 Day 2, 100 mg on Week 1 Day 3, 200 mg on Week 1 Day 4, and 400 mg on Week 1 Day 5 and thereafter, once daily, until the end-of-treatment. The dose of venetoclax may have been increased to 600 mg QD at Week 8 or thereafter.
Study NCT03873493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib capsules taken orally once a day, 420 mg/day until the end-of-treatment.
Study NCT03258333 — intervention group
Intervention type: PROCEDURE
Intervention: aortic valve replacement
Description: Standart AVR using stented stented bioprosthesis aortic valve reconstruction using autologus pericardium
Study NCT03756350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1060nm diode laser
Description: Non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1060nm diode laser applicators which are 60x60 mm in size. There is a belt included with the system to allow for the secure application of the applicators to the treatment area.
Study NCT03157232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rainbow DCI and R1-25 sensor
Description: Noninvasive Measurement of SpHb
Study NCT05241509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cymbopogon citratus (lemongrass) oil gel
Description: Biochemical Efficacy of Cymbopogon Citratus Gel as Local Drug Delivery Agent in Reducing Matrix Metalloproteinase-8 Levels Intra-crevicularly in the Treatment of Stage II Periodontitis
Study NCT05241509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cymbopogon citratus (lemongrass) oil gel
Description: Biochemical Efficacy of Cymbopogon Citratus Gel as Local Drug Delivery Agent in Reducing Matrix Metalloproteinase-8 Levels Intra-crevicularly in the Treatment of Stage II Periodontitis
Study NCT02206165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan 8mg
Description: Once a day, 8 weeks
Study NCT02206165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan 8mg
Description: Once a day, 8 weeks
Study NCT02206165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan 16mg
Description: Once a day, 8 weeks
Study NCT02206165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan 16mg
Description: Once a day, 8 weeks
Study NCT02206165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5mg
Description: Once a day, 8 weeks
Study NCT02206165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: Once a day, 8 weeks
Study NCT02206165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 10mg
Description: Once a day, 8 weeks
Study NCT02206165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg
Description: Once a day, 8 weeks
Study NCT05370066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CS6BP watches will be used in the study.
Description: CS6BP watches will be used with FDA approved Blood pressure monitors
Study NCT03343951 — intervention group
Intervention type: OTHER
Intervention: Examination
Description: Patients will be examined twice the same day by an extended scope physiotherapist (ESP) and an orthopaedic surgeon (OS) in random order. They will independently and blinded to each other's opinion register~* diagnosis and treatment plan (including need for further diagnostic examinations - i.e. imaging)~* if the patient needs a new appointment at the shoulder clinic~* if they under usual conditions would discuss their results with the opposite health professional before deciding diagnosis and treatment plan.~After the individual examinations the ESP and OS discuss their results and come to an agreement (common decision) regarding the patient's diagnosis, treatment plan and need of a new appointment. Patients will be informed only of the common decision of the ESP and OS.
Study NCT04162925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer screening education for breast, colon and oral cancers
Description: Bedside education one-on-one by showing screening video and handouts at the end of educational session for breast, colon and oral cancer. Patient who are agreeable to oral cancer screen during hospitalization perform oral cancer screening
Study NCT03268733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Tablet 5 mg
Study NCT01256658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COA566
Description: COA566 tablets or dispersible tablets twice daily during 3 days; dosage according to body weight.
Study NCT02614534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MITOMYCIN-C 30 mg
Description: Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women) plus HIPEC with Mytomicin C for 60 minutes.
Study NCT02614534 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proactive cytoreductive surgery
Description: Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women)
Study NCT02350179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: This will be a prospective, randomized controlled trial that will be carried at Obstetrics and Gynecology Department, Ain Shams Maternity Hospital.~The study will include 100 pregnant women with singleton fetus 38 or more weeks gestation who will be divided in to two groups.~Study group will include 50 women and control group will include 50 women. Women assigned to the study group will receive 1 gr of TXA injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.~The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
Study NCT02350179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
Study NCT03298568 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DAOsin
Description: DAOsin is a food supplement for special medical purpose for the treatment of food intolerance provoked by histamine intake.
Study NCT01440777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Go! to Sleep
Description: The online program provides various tools for the delivery of the intervention including:~* Daily articles~* Daily activities to help get the sleep you need~* Daily sleep improvement recommendations~* Audio recorded relaxation exercises~* Daily e-mails from your program coach~* Personal progress charts~* An online sleep log and daily sleep score
Study NCT03726580 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: Assess the effect of isoflurane, sevoflurane, propofol and regional anesthesia on the olfactory threshold, olfactory identification and endocrine regulation of associative memory in the postoperative period in old age group.
Study NCT01551186 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Description: 1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
Study NCT01571765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MNCH programming in health district
Description: training at health district level in management, data collection. Training at health centres in obstetrics and pediatrics and training in community of CHWs and bednet distribution
Study NCT00752531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Automated Telemanagement (HAT)
Description: The HAT was designed as an Internet-based telemedicine system that (1) provides ongoing education to patients about their chronic disease, (2) helps patients follow their self-care plans, and (3) helps health care practitioners monitor their patients' self-management processes according to current clinical guidelines. During each telecommunication session, patients perform self-testing and receive structured disease-specific education, patient-tailored counseling, and advice on how to follow their individual self-care plans based on the current results of self-testing.
Study NCT02877472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: porous tantalum rod
Description: Patients with avascular necrosis of the femoral head after femoral head fracture surgery receive treatment of core decompression and porous tantalum rod implantation
Study NCT02877472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: core decompression
Description: Patients with avascular necrosis of the femoral head after femoral head fracture surgery will undergo core decompression.
Study NCT01418820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum stimulation
Description: 10 days (2x 5 working days), daily transorbital alternating current stimulation (rtACS) is applied with a device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 µA. Current intensity is individually adjusted according to how well patients perceived phosphenes, e.g. any sensation of flickering light in response to the rtACS stimulation. Stimulation frequencies were between the individual alpha frequency peak and below flicker fusion.
Study NCT01418820 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo stimulation
Description: 10 days (2x 5 working days), daily sham-stimulation with the same electrode montage set-up that is used for verum transorbital alternating current stimulation (rtACS). Minimal sham-stimulation was performed with single bursts (approx. one per min) of electrical currents at a given frequency of 5Hz and individually adjusted current amplitude.
Study NCT06402981 — intervention group
Intervention type: OTHER
Intervention: High risk prediction model for liver injury
Description: Risk Prediction Model for Liver Injury After Use of PD-1/PD-L1 Inhibitors
Study NCT02183532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS
Description: single dose
Study NCT02183532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356 BS
Description: multiple doses
Study NCT01238367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Subjects will receive recombinant factor VIII (N8) at a dose of 50 +/- 5 IU/kg body weight. Intravenous administration as a single bolus injection.
Study NCT03307499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeoPatch
Description: NeoPatch as an adjunct to foot and ankle tendon revision/repair surgery
Study NCT03529695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard HVP Curriculum
Description: Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on strengthening children's cognitive skills, early literacy skills, social/emotional and physical development.
Study NCT03529695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard HVP Curriculum
Description: Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on strengthening children's cognitive skills, early literacy skills, social/emotional and physical development.
Study NCT03529695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obesity Prevention
Description: Obesity prevention curriculum program targets 4 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, and decreasing fried foods) aimed at reducing obesity risk in mothers and children. The module will also include weekly activity opportunities to develop social networks that foster healthy eating and physical activity.
Study NCT04322890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 80mg, po, qd;
Study NCT04322890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib 150 MG
Description: Alectinib 600mg, po, qd; Lorlatinib, 100mg, po, qd;
Study NCT04322890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 MG
Description: Crizotinib 250 MG po bid.
Study NCT04322890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib, Crizotinib.
Description: Savolitinib, 300mg po qd.
Study NCT04322890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: 500mg, ivgtt, every 21day.
Study NCT03236246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRX-0502
Description: Oral ferric citrate with meals
Study NCT05817760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Z-scrotoplasty
Description: Z shape incision of the penoscrotal web and closure
Study NCT05817760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heineke-Mikulicz scrotoplasty
Description: Transverse incision of the penoscrotal web with vertical closure
Study NCT03249077 — intervention group
Intervention type: BEHAVIORAL
Intervention: Digital DPP
Description: The online DPP program is 12 months in duration with 16 core sessions delivered over 16-26 weeks and 6 maintenance sessions delivered over 6 months.
Study NCT03249077 — intervention group
Intervention type: BEHAVIORAL
Intervention: In-person DPP
Description: The in-person DPP program is 12 months and consists of weekly sessions for the first 6 months and monthly sessions for the remaining 6 months.
Study NCT03249077 — intervention group
Intervention type: OTHER
Intervention: DPP not enrolled
Description: Access to usual care services without restrictions.
Study NCT00462865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Capecitabine and Avastin
Description: avastin administered concurrently with chemotherapy (gemcitabine + capecitabine) for six cycles followed by single agent avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
Study NCT02410941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical decision support
Description: Establish evidence-based standardized clinical pathways implemented by local communities of practice focused on imaging utilization in ED settings as models of participatory research and integrated knowledge translation.
Study NCT01398293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 100 mg single dose orally
Study NCT01398293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: 400 mg single dose orally
Study NCT01398293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danoprevir placebo
Description: single oral dose
Study NCT01398293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: danoprevir placebo
Description: single oral dose
Study NCT01398293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: 400 mg single dose orally
Study NCT01398293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin placebo
Description: single oral dose
Study NCT01398293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: moxifloxacin placebo
Description: single oral dose
Study NCT01398293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg single dose orally
Study NCT01398293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir placebo
Description: single oral dose
Study NCT01398293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ritonavir placebo
Description: single oral dose
Study NCT02328287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLOB®
Description: Each patient will undergo a single administration of ALLOB® into the failed fusion lumbar level under anesthesia.